

**RECEIVED  
CENTRAL FAX CENTER**

**MAY 25 2006**

Attorney Docket No.: 6207.520 -US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Pingel et al.

Application No.: 10/725,843

Group Art Unit: 1656

Filed: December 2, 2003

Examiner: Sheridan Swope

For: Factor VII Glycoforms

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is being filed in response to the Restriction Requirement mailed December 1, 2005. The Examiner requested restriction between one of the following invention groups:

Group I (claims 1-17 and 22)<sup>1</sup>: directed to a method for large-scale production of Factor VII;

Group II (claims 18-19), directed to a Factor VII polypeptide;

Group III (claims 20, 21), directed to a composition; and

Group IV (claims 23 and 24, directed to methods of treatment.

Applicants elect to prosecute the invention of Group I in this application, with traverse. Applicants reserve the right to pursue non-elected subject matter in divisional applications.


---

<sup>1</sup> It is believed that the Examiner included claims 17 and 22 in Group I in error, as they are directed to a polypeptide and formulation, respectively.

It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Date: May 25, 2006

Respectfully submitted,



Reza Green, Reg. No. 38,475

Novo Nordisk Inc.

Customer Number 23650

(609) 987-5800

Use the following customer number for all correspondence regarding this application.

**23650**

PATENT TRADEMARK OFFICE